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SUMOylation of sPRDM16 promotes the
progression of acute myeloid leukemia
Song Dong and Jieping Chen*
Abstract
Background: In addition to genetic and epigenetic alteration, post-translational modification of proteins plays a
critical role in the initiation, progression and maturation of acute myeloid leukemia (AML).
Methods: The SUMOylation site of sPRDM16 at K568 was mutated to arginine by site-directed mutagenesis. THP-1
acute myeloid leukemia cells were transduced with a lentivirus containing wild type or K568 mutant sPRDM16.
Proliferation, self-renewal and differentiation of transduced THP-1 cells were analyzed both in vitro cell culture and
in mouse xenografts. Gene expression profiles were analyzed by RNA-seq.
Results: Overexpression of sPRDM16 promoted proliferation, enhanced self-renewal capacity, but inhibited differentiation
of THP-1 acute myeloid leukemia cells. We further confirmed that K568 is a bona fide SUMOylation site on sPRDM16.
Mutation of the sPRDM16 SUMOylation site at K568 partially abolished the capacity of sPRDM16 to promote proliferation
and inhibit differentiation of acute myeloid leukemia cells both in vitro and in mouse xenografts. Furthermore, THP-1 cells
overexpressing sPRDM16-K568R mutant exhibited a distinct gene expression profile from wild type sPRDM16 following
incubation with PMA.
Conclusions: Our results suggest that K568 SUMOylation of sPRDM16 plays an important role in the progression of acute
myeloid leukemia.
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Background
Acute myeloid leukemia (AML) is a serious disease of the
hematopoietic system characterized by de-differentiation
and uncontrolled proliferation of immature hematopoietic
precursor cells in the bone marrow [1]. Leukemia results
from the accumulation of genetic and epigenetic alter-
ations during the multistep process of tumorigenesis,
including activation of oncogenes and/or inactivation of
tumor suppressor genes. Many transcription factors have
been shown to play an important role in aggressive
hematological tumors. Within the past decade evidence
that post-translational modification of proteins, including
phosphorylation [2], acetylation [3], ubiquitination [4] and
SUMOylation [5, 6], plays a critical role in the initiation,
progression and maturation of AML has accumulated.
Positive regulatory domain I-binding factor 1 and
retinoblastoma-interacting zinc finger protein-1 (PRDM16)
is a transcription factor [7]. PRDM16 is also termed MEL1
because it shares 63 % sequence similarity with PRDM3/
MECOM (MDS1 and EVI1 complex) [8]. PRDM16
encodes two isoforms: the full-length PRDM16 (or MEL1)
and the short-form sPRDM16 (or MEL1S) [9]. PRDM16,
but not sPRDM16, contains a 134-amino acid PR domain,
which is highly homologous to the SET domain, a struc-
tural hallmark of histone methyltransferases [7, 10].
PRDM16 plays an important role in palatogenesis [11],
maintenance of hematopoietic [12] and neuronal stem cells
[13], and adipose tissue differentiation [14–17]. It acts as an
H3K9me1 methyltransferase, which is required to maintain
the integrity of mammalian heterochromatin [7, 9, 10, 18].
PRDM16 is reported to contribute to translocation-induced
leukemia [7, 9, 10, 18]. However, only the PR domain-
negative isoform of sPRDM16 is potentially oncogenic in
leukemia [10], and the underlying molecular mechanisms
are largely unknown.
Small ubiquitin-related modifier (SUMO) is a highly
conserved ubiquitin-like protein which acts as a reversible
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and highly dynamic post-translational modifier of a large
number of proteins [19, 20]. SUMOylation is catalyzed by
a multistep enzymatic cascade including activating (E1),
conjugating (E2), and ligating (E3) enzymes. SUMOylation
alters the localization, activity or stability of target proteins
[19], and is reversed by a family of Sentrin/SUMO-specific
proteases (SENPs).
Accumulating evidence has shown that SUMOylation
plays a wide range of roles in the regulation of growth
and development of all eukaryotes, for example, influen-
cing transcriptional regulation and genome integrity.
Deregulation of SUMOylation has been found in
many human diseases including cancer, seizures and
Alzheimer’s diseases [21]. Recently, sPRDM16 was
reported to be SUMOylated [22], and we have found
PRDM16 to also be SUMOylated (data not shown).
However, the role of PRDM16 SUMOylation in pro-
gression of AML is unknown.
In this study, we have explored sPRDM16 SUMOyla-
tion in AML in vivo and in vitro. We found that
SUMOylation of sPRDM16 regulated expression of
genes during AML differentiation, and promoted AML
progression while inhibiting differentiation of AML cells.
Methods
Plasmids and antibodies
The plasmid MSCV-PRDM16 was purchased from
Addgene (Cambridge, MA, USA). Plasmid FLAG-
sPRDM16 was generated from MSCV-PRDM16 by stand-
ard molecular cloning methods. Plasmids HA-SUMO1,
HA-UBC9, RGS-SENP1 and RGS-SENP1-mutant were
designed and developed as previously described [23].
Anti-Flag antibody was obtained from Sigma (clone M2,
St. Louis, MO, USA); anti-HA antibody was purchased
from COVANCE (Beijng, China); anti-RGS antibody was
obtained from QIAGEN (Germantonw, MD, USA); and
anti-SUMO1 and PRDM16 antibodies from Abcam
(Cambridge, MA, USA).
Site-directed mutagenesis
The potential SUMOylation residues from lysine (K)
to arginine (R) in sPRDM16 were mutated using the
QuickChangeTM site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA).
FLAG-sPRDM16-K568R was generated with the fol-
lowing primers:
Sense 5′-TTGCTGGTCAGGGCTGAGCCA -3′ and
Antisense 5′-TGGCTCAGCCCTGACCAGCAA-3′.
Cell culture
HEK293T cells were cultured in DMEM (Hyclone) sup-
plemented with 10 % fetal bovine serum (Gibco) and
1 % penicillin-streptomycin (Gibco). THP-1 cells were
maintained at 37 °C with 5 %CO2 in RPMI-1640 Medium
(Hyclone) supplemented with 0.05 mM 2-mercaptoethanol
(Sigma) and 10 % fetal bovine serum (Gibco). Plasmids
were transiently transfected into HEK293T cells using
LipofectamineTM2000 (Invitrogen) according to manufac-
turer’s instructions.
Evaluation of cell adherence (morphological
differentiation)
Differentiation of THP-1 cells to macrophage-like cells
was assessed by measureing adherence to plastic cell
culture wells. Log phase cells were centrifuged and
resuspended at at 1 × l06 cell/ml in fresh RPMI1640
complete medium containing 3 nM PMA and incubated
for 24 h. Nonadherent cells were collected from the
supernatant after washing, then adherent cells were
separated gently by cell scraper on ice. The adherent
and non-adherent cells were counted, and the sum
correlated well with the original number of cells plated.
To evaluate of differentiation, control and treated cells
were removed from the Petri dishes, pelleted by centrifu-
gation, and resuspended in 1 ml fresh medium.
Western blot
Total protein was extracted from cells or tissues using
radioimmune precipitation assay (RIPA) buffer (50 mM
Tris-HCl pH7.4, 150 mM NaCl, 1 % NP-40, 0.1 % SDS,
1 mM EDTA) with 1 % protease inhibitor cocktail. Equal
amounts of protein extracts (40 μg) were separated by
10 % sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred onto a PVDF mem-
brane. Membranes were blocked with 5 % w/v non-fat dry
milk dissolved in Tris-buffered saline plus Tween-20
(TBS-T; 0.1 % Tween-20; pH 8.3) at room temperature for
1 h, and incubated with primary antibodies at 4 °C
overnight. After washing with TBS-T, membranes were
incubated with horseradish peroxidase (HRP)-labeled
secondary antibodies for 1 h at room temperature. Immu-
nobands were visualized using enhanced chemilumines-
cence (ECL) kit (GE Healthcare, Waukesha, WI, USA)
according to manufacturer’s instructions and exposed to
X-ray films.
Immunoprecipitation
Cells were collected at 48 h after transfection and lysed
using an ice-cold RIPA buffer (50 mM Tris-HCl pH7.4,
150 mM NaCl, 1 % NP-40, 0.1 % SDS, 1 mM EDTA)
with 10 mM N-ethylmaleimide, 1 mM PMSF and protease
inhibitors (Roche). Cell lysis was performed on ice for
20 min and the cell lysate was sonicated for 5 s three
times. After centrifugation at 14,000 g for 10 min at 4 °C,
the supernatants were added to the appropriate antibody
coupled to 20 μl of anti-FLAG M2 agarose beads (Sigma).
The bead suspension was incubated at 4 °C for 2 h on a
rotating shaker. Beads were then washed 5 times with
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RIPA buffer, mixed with 15 μL 2× SDS sample buffer and
boiled at 100 °C for 5 min. The samples were subjected to
Western blot analysis.
Lentiviral transduction
To obtain lentivirus particles, 5 × 105 HEK293T pack-
aging cells were plated in 60-mm culture dishes and
transiently transfected with 2 μg of each lentivirus vector
mixture (pCDH-sPRDM16 1 μg, psPAX2 0.75 μg,
pMD2.G 0.25 μg) together with 5 μl Lipofectamine 2000
(Invitrogen). Supernatant containing lentivirus was
collected 36 h after transfection, filtered using 0.45-mm
filters and used immediately for infection. Logarithmically
growing THP-1 cells were transduced with lentivirus as
previously described [24].
Cell proliferation assays
To assess cellular proliferation, cells were seeded in
24-well plates (2 × 105 cells in 1 ml medium per well)
and counted each day using a hematocytometer and
trypan blue staining to exclude dead cells. Colorimetric
proliferation assays were performed in 96-well plates
as 8-fold measurements. A WST-8 [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tet
razolium, monosodium salt] assay (Dojindo, Shanghai,
China) was conducted using 2000 cells in 100 μl medium
per well in 96-well plates. The cell counting kit-8 (CCK-8)
assay was performed according to the manufacturers’
recommendations.
Soft agar colony formation assay
A soft agar suspension (0.35 % agar) containing colony-
forming cells was plated over a soft agar underlay
(0.6 % agar). THP-1 cell complete culture medium
was added and changed twice a week. After 1000 cells
were embedded in the soft agar in 6-well plates (end
concentration 0.35 % agar in complete medium) and
grown over 12 days, colony numbers were counted
under microscope.
Flow cytometry
For flow cytometry, cells were fixed with 4 % parafor-
maldehyde in PBS for 10 min and then blocked with 1 %
BSA in PBS for 10 min at room temperature. Fixed,
blocked cells were incubated with APC-conjugated
anti-CD11b monoclonal antibody (BD PharMingen) for
15 min on ice, and cells were washed 3 times with 1 %
BSA in PBS. Staining was analyzed using a FACS
Calibur instrument (BD PharMingen).
Animal systemic leukemia models
NOD.CB17-Prkdcscid/J (NOD/SCID) mice were pur-
chased from Shanghai SLAC laboratory Animal Co., Ltd.
(Shanghai, China). Animals were maintained at the animal
facility of Shanghai Jiao Tong University School of
Medicine in accordance with the local regulations and
handled under sterile conditions. The study protocol was
approved by the Review Committee for the Use of Human
or Animal Subjects of Shanghai Jiao Tong University
School of Medicine. Transplantations were performed by
intravenous injections of six to eight week old mice. THP-1
cells (1 × 107 cells per mouse in 200 ml saline vehicle) were
injected into the tail vein to create the leukemia models 5 h
after total body irradiation with 1.5 Gy using a 137Cs
source to enhance angiogenic potential [25]. After trans-
plantation, the mice were monitored for leukemia symp-
toms, such as weight loss, hunch-back, and decreased
activity. All procedures were carried in accordance with
national and international laws and policies.
MRNA-sequencing and data analysis
RNAs from the THP-1 cell line with stable expression
of sPRDM16-WT or sPRDM16–K568R or a mock-
transfected cell line were purified using TrizolTM
method and subsequently cleaned using RNAeasy Kit
(Qiagen). The polyadenylated RNAs purified from the
cells were used for the construction of a sequencing
library using the ScriptSeq Complete Gold Kit (Epicentre,
Illumina). Cluster generation and sequencing were carried
out using standard procedures in Hi-Seq 2500 Illumina
platform. We used a single-end sequencing protocol to
generate a 50 nt read at each end. RNA-seq reads were
aligned to the human genome using TopHat (Johns
Hopkins University, Baltimore, MD, USA). Cufflinks was
employed to normalize Data and perform relevant
comparisons among the different samples. Gene ontology
analysis was performed using DAVID GO analysis soft-
ware to search for enriched pathways.
Quantitative real-time PCR analysis
Total RNA was extracted by Trizol kit (Invitrogen) and
treated with DNase (Promega). Complementary DNA was
reverse transcribed using M-MLV reverse transcriptase and
random hexamers according to the manufacturer’s protocol
(Takara). All experiments were performed with Power
SYBR® Green PCR Master Mix (Applied Biosystems) using
the LightCycler® 480 Real-Time PCR System (Roche). PCR
was carried out in triplicate and standard deviations repre-
senting experimental errors were calculated. Differences in
cDNA input were normalized to GAPDH. All data were
analyzed by the LightCycler® 480 software (Roche). The
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Fig. 1 (See legend on next page.)













Results were expressed as relative expression, normal-
ized to the internal control.
Statistical analysis
All data are presented as mean ± standard deviation (S.D.).
Statistical analysis was performed using Student’s t-test and
values of P ≤ 0.05 were considered statistically significant.
Results
sPRDM16 promotes proliferation, enhances self-renewal
capacity, while inhibiting differentiation of acute myeloid
leukemia cells
Protein expression of sPRDM16 wasn’t detected in THP-1
or NB4 cell line (Fig. 1a) and very few leukemic cell lines
express sPRDM16 [10]. To investigate the role of sPRDM16
in AML progression, we cloned the DNA fragment from
the internal initiation codon ATG597 in exon 4 to exon 17
of PRDM16 into the PCDH lentivirus vector with FLAG-
tag at the N-terminal, and established stablly infected cell
lines. We first monitored the proliferation of THP-1 cells
stably transfected with either vector (Vector-THP-1) or
sPRDM16 (sPRDM16-WT-THP-1). We found that cells
overexpressing sPRDM16 proliferated more rapidly than
Vector-THP-1-transfected cells (Fig. 1b). Similar results
were obtained by CCK-8 assay (Fig. 1c).
To assess whether sPRDM16 enhanced self-renewal of
leukemia cells, we performed a soft agar colony forma-
tion assay in the presence of 10 % FBS and monitored
cell growth. After 12 days, sPRDM16-WT-THP-1 cells
had formed more soft agar colonies than Vector-THP-1
cells (P < 0.01) (Fig. 1d and e.
To determine whether sPRDM16 played a role in the
maturation of AML cells, we incubated THP-1 cells with 3
nM PMA for 24 h, and measured cell-surface expression of
the monocytic maturation marker CD11b using APC-
labeled anti-CD11b antibody by flow cytometry (Fig. 1f).
Expression of CD11b did not differ significantly between
Vector-THP-1 (8.02 %) and sPRDM16-WT-THP-1 (10.3 %)
cells. PMA induced expression of CD11b in 45.4 % of
sPRDM16-WT-THP-1 cells, while a significant increase in
CD11b expression was observed in Vector-THP-1 cells
(76.4 %, P < 0.01) (Fig. 1f and g). Further, when cell adher-
ence was monitored, as an indication of monocyte differen-
tiation, sPRDM16-WT-THP-1 cells demonstrated less
adherence (Fig. 1h).
These results indicate that sPRDM16 promoted prolifer-
ation and enhanced self-renewal capacity, while inhibing
cellular differentiation in AML, suggesting that sPRDM16
may be an oncogene.
K568 is a bona fide SUMOylation site of sPRDM16
Overexpression of sPRDM16 with loss of p53 induces
myeloid leukemia in mice [10]. It was also reported that
SUMOylation of sPRDM16 leads to its interaction with
CtBP, facilitating the repressor activity of CtBP and block-
ade of G-CSF-induced myeloid differentiation in L-G3
(See figure on previous page.)
Fig. 1 sPRDM16 promoted the proliferation, enhanced the capacity for self-renewal and inhibited the differentiation of acute myeloid leukemia
cells. a Protein levels of sPRDM16 in THP-1 and NB4 cell lines. The original whole-cell lysates (WCL) were analyzed by immunoblotting (IB) with
anti-PRDM16 or anti-actin antibodies. b Overexpression of sPRDM16 promoted proliferation of THP-1 cells. THP-1 cells stably transfected
with either vector (Vector-THP-1) or sPRDM16 (sPRDM16-WT-THP-1) were cultured and cell number was counted at the indicated time.
Data are presented as mean ± S.D. of three independent experiments in RPMI-1640 medium. The number of vector and sPRDM16 differed
significantly at 48 h (P < 0.01). c Proliferation of the THP-1 cells was determined using CCK-8 assay. The absorbance of the CCK-8 assay
solution was detected with plate reader (450 nm filter). Data are presented as means ± S.D. of three independent experiments. Difference
between two cell lines was significant at 48 h (P < 0.01). d Overexpression of sPRDM16 increased colony formation of THP-1 cells. THP-1
cells stably transfected with either vector (Vector-THP-1) or sPRDM16 (sPRDM16-WT-THP-1) were seeded in 1 ml of medium containing
10 % FBS with 0.35 % soft agar at 1 × 103 cells per well and layered onto the base soft agar medium. The photographs were taken after
12 days. Images are representative of three independent experiments. e The number of colonies in colony formation assay was scored
after 12 days. The colonies were visualized by staining with 0.5 % crystal violet. The experiments were analyzed in triplicate and colonies
larger than 50 μm in diameter were counted under microscope. Columns, mean of triplicate experiments; bars, S.D. An unpaired (equal
variance) t-test was performed to compare sPRDM16–WT and vector control (* * P < 0.01). f Overexpression of sPRDM16 suppressed differentiation of
THP-1 cells. Logarithmically growing cells were exposed to 3 nM PMA for 24 h. The percentage of cells expressing the monocytic maturation marker
CD11b was determined by flow cytometry. The results are representative of three independent experiments. g The results of flow cytometry were
represented as a histogram. Values represent the mean ± S.D. for experiments performed in triplicate. *P < 0.01 represents a significant difference from
the cells treated with PMA (n= 3); columns, mean of triplicate experiments; bars, S.D. h The same THP-1 cells were treated as E. Logarithmically growing
cells were treated with 3 nM PMA for 24 h. The percentage of adherent cells was calculated. Values represent the mean ± S.D. for experiments performed
in triplicate. *P< 0.01 represents a significant difference from cells treated with PMA (n= 3); columns, mean of triplicate experiments; bars, S.D.
Dong and Chen BMC Cancer  (2015) 15:893 Page 5 of 13
cells [22]. Thus, we speculated that sPRDM16 SUMOyla-
tion may contribute to AML progression. To test this
hypothesis, we first confirmed that sPRDM16 was
SUMOylated by SUMO1. We co-transfected HEK293T
cells with Flag-sPRDM16, HA-SUMO1 and HA-UBC9
plasmids, and performed co-immunoprecipitation assay.
As show in Fig. 2a, sPRDM16 was conjugated to SUMO1.
Next, we co-expressed Flag-sPRDM16, HA-SUMO1 and
SENP1 in HEK293T cells. SUMOylated sPRDM16 was
readily detected when Flag-sPRDM16 and HA-SUMO1
were co-transfected. In sharp contrast, the SUMOylated
band disappeared when wild type SENP1 was over-
expressed, but not when the catalytic mutant SENP1m was
expressed (Fig. 2b). To confirm that the SUMO acceptor
site of sPRDM16 was K568, we generated sPRDM16
SUMOylation mutant, sPRDM16-K568R and performed
SUMOylation assays in HEK293T cells co-transfected with
wild-type sPRDM16-WT or mutant sPRDM16-K568R and
HA-SUMO1. As expected, one band of SUMOylated Flag-
sPRDM16 was observed in the immunoprecipitates of cells
transfected with sPRDM16–WT. In contrast, the mutant
sPRDM16-K568R completely abolished SUMOylation
(Fig. 2c), consistent with the hypothesis that K568 is a bona
fide SUMOylation site of sPRDM16 [22].
Fig. 2 sPRDM16 was SUMOylated by SUMO1 on lysine-568. a sPRDM16 was SUMOylated in vivo. HEK293T cells were transfected with the indicated
plasmids for 36 h. Immunoprecipitation was performed with anti-FLAG M2 agarose beads. The immunoprecipitates (IP) and the original whole-cell
lysates (WCL) were analyzed by immunoblotting (IB) with anti-HA or anti-FLAG antibodies. b SENP1 de-SUMOylated sPRDM16. HEK293T cells were
transfected with HA-SUMO1, Flag-sPRDM16, RGS-SENP1, or RGS-SENP1m as indicated. Flag-sPRDM16 proteins were pulled down by
anti-Flag M2 agarose beads from cell lysates. Bound proteins were blotted with anti-Flag. Cell lysate was immunoblotted (IB) with
anti-Flag antibody, anti-HA antibody, or anti-RGS antibody. c K568 was the primary SUMOylation site of sPRDM16. HEK293T cells were
transfected with the indicated plasmids. Cell lysates were immunoprecipitated with anti-FLAG M2 agarose beads, followed by Western
blot (WB) analysis using anti-HA or anti-FLAG antibodies
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SUMOylation contributes to sPRDM16-mediated
tumorigenesis in acute myeloid leukemia
To explore the function of sPRDM16 SUMOylation in
progression of AML, we generated stable THP-1 cell lines
by polyclonal lentiviral infections with Lenti-Vector,
sPRDM16-WT or sPRDM16–K568R. Exogenous protein
level of sPRDM16 or K568R in THP-1 cell line was shown
in (Fig. 3a). We first performed a soft agar colony-forming
assay in the presence of 10 % FBS. sPRDM16-WT-THP-1
and sPRDM16-K568R-THP-1 cells formed more numer-
ous and larger colonies than Lenti-Vector transfected cells
(Fig. 3b and c). However, colony formation was slower in
sPRDM16-K568R transfected cells than sPRDM16-WT-
THP-1, suggesting that sPRDM16–K568R reduced the
capacity of self-renewal (Fig. 3b and c).
To determine whether SUMOylation of sPRDM16 was
involved in differentiation of AML cells, we treated cells
stably transfected with Lenti-Vector, sPRDM16–WT and
sPRDM16–K568R with 3 nM PMA for 24 h and measured
cell surface expression of the monocytic maturation marker
CD11b by flow cytometry. Incubation with PMA signifi-
cantly increased expression of CD11b in Vector-THP-1,
sPRDM16-WT and sPRDM16-K568R-THP-1 cells. How-
ever, PMA stimulated CD11b expression less potently in
sPRDM16-WT-THP-1 cells (45.4 %) than sPRDM16-
K568R cells (54.6 %) (Fig. 3d and e). Similarly, when cell
adherence was monitored, as a marker of monocyte
differentiation, sPRDM16-WT-THP-1 cells adhered less
well than sPRDM16-K568R cells (Fig. 3f). Meanwhile,
sPRDM16 SUMOylation was decreased in sPRDM16-WT-
THP-1 cells after incubation with PMA (Fig. 3g).
These results suggest that mutation of sPRDM16
SUMOylation site at K568 reduced the capacity of
sPRDM16 to induce proliferation and inhibit differenti-
ation of AML cells, suggesting that K568 SUMOylation
of sPRDM16 played an important role in the pathogen-
esis of AML.
SUMOylation of sPRDM16 enhances the engraftment
of systemic THP-1 transplantation leukemia in
NOD.CB17-Prkdcscid/J (NOD/SCID) mice
To confirm our observations in vivo, we transplanted
sub-lethally irradiated mice with 1 × 107 GFP-labeled
THP-1 cells stably infected with Lenti-Vector, sPRDM16–
WT or sPRDM16–K568R. The fluorescent disseminated
leukemia grafts were monitored by flow cytometry for
30 days post-transplantation. As shown in Figs. 4a and b,
in bone marrow fractions, the frequency of GFP + cells in
the Lenti-Vector-transplanted group was lower than in
either sPRDM16-WT-transplanted or sPRDM16-K568R-
transplanted animals. However, the frequency of GFP +
cells in the sPRDM16-WT-transplanted groups was higher
than in the sPRDM16-K568R-transplanted group. Similar
results were observed in analysis of mouse peripheral
blood (Fig. 4c and d). To investigate the engraftment of
leukemic cells in bone marrow, we subsequently sectioned
the bone marrow tissues and conducted hematoxylin and
eosin (H&E) staining (Fig. 4e). We also continuously mon-
itored the body weight of mice. Consistent with the flow
cytometry results, sPRDM16-WT-transplanted animals
lost more weight than sPRDM16-K568R-transplanted and
the Lenti-Vector-transplanted animals (Fig. 4f). But the
difference was not statistically significant. Taken together,
these results indicate that sPRDM16 SUMOylation
enhanced engraftment of systemic THP-1 transplantation
leukemia in NOD.CB17-Prkdcscid/J (NOD/SCID) mice,
suggesting that mutation of sPRDM16 K568R partially
attenuates the progression of AML in vivo.
Differentiation-related genes induced by PMA are
differentially expressed between THP-1 cells stably
expressing sPRDM16-WT and sPRDM16–K568R
To further investigate the physiological significance of
sPRDM16 SUMOylation, we conducted high-throughput
sequencing of mRNA (mRNA-seq) with THP-1 cells
(See figure on previous page.)
Fig. 3 SUMOylation was required for sPRDM16 in the progression of acute myeloid leukemia. a Exogenous protein expression of sPRDM16 or K568R in
THP-1 cell line. The original whole-cell lysates (WCL) were analyzed by immunoblotting (IB) with anti-FLAG or anti-actin antibodies. b THP-1 cells stably
transfected with either vector, sPRDM16 or sPRDM16-K568R were seeded in 1 ml of medium containing 10 % FBS with 0.35 % soft agar at 1 × 103 cells per
well and layered onto the base soft agar medium. Photographs were taken after 12 days. Images are representative of three independent experiments. c
The number of colonies of colony formation assay (A) was scored after 12 days. The colonies were visualized by staining with 0.5 % crystal
violet. The experiments were analyzed in triplicate and colonies larger than 50 μm in diameter were counted under microscope. Columns, mean of
triplicate experiments; bars, S.D. (* * P< 0.01). d Logarithmically growing THP-1 cells stably transfected with either sPRDM16 or sPRDM16-K568R vector,
were exposed to 3 nM PMA for 24 h. The percentage of cells expressing the monocytic maturation marker CD11b was determined by flow cytometry.
The dot plot results are representative of three independent experiments. e The results of flow cytometry described in Fig. 3C were represented as a
histogram. Values represent the mean ± S.D. for experiments performed in triplicate. *P < 0.01 represents a significant difference from the cells treated
with PMA (n = 3); columns, mean of triplicate experiments; bars, s.d. f Logarithmically growing THP-1 cells were treated with 3 nM PMA for
24 h. The percentages of adherence cells on the surface of plastic dish were counted. Values represent the mean ± S.D. for experiments performed in
triplicate. *P < 0.01 represents a significant difference from the cells treated with PMA (n = 3). Columns, mean of triplicate experiments; bars, S.D. g
sPRDM16 SUMOylation in THP-1 cells stably expressing sPRDM16-WT was decreased after incubation with PMA. SUMO1-conjugated proteins in THP-1
cells in the presence or absence of PMA for 24 h were immunoprecipitated with anti-FLAG M2 agarose beads. SUMO1-sPRDM16 proteins were blotted
with anti-FLAG and anti-SUMO1. Cell lysate was immunoblotted with anti-FLAG and anti-FLAG antibody
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expressing sPRDM16-WT and sPRDM16-K568R. We
analyzed the impact of sPRDM16 SUMOylation global
gene expression induced in leukemia cell differentiation
using gene ontology. From 10 million 50 bp single-end
reads, we identified 237 genes the expression of which
differed significantly between sPRDM16-WT-THP-1 and
sPRDM16-K568R-THP-1 cells after incubation with PMA
(>1.5-fold with adjusted P < 0.05). Based on gene ontology
results, sPRDM16 SUMOylation significantly affected the
expression of cancer-related genes, including genes impli-
cated in wound response, cell proliferation, chemotaxis,
differentiation, and cell cycle progression (Fig. 5a). The
findings suggest that SUMOylation of sPRDM16 was
involved in cancer cell proliferation and differentiation.
Such functional enrichment is not surprising as sPRDM16
is a transcriptional regulator of proliferation and differen-
tiation of hematopoietic cell and adipose differentiation.
We next summarized two clusters of gene annotation
and selected 13 genes involved in hematopoietic cell
proliferation and differentiation (Fig. 5b). We subse-
quently validated the mRNA-seq results by measuring
the changes in 7 newly identified targets, which were
previously implicated in hematopoietic cell proliferation
and differentiation. The selected targets of sPRDM16
SUMOylation were further validated by real-time RT-
PCRs. The RT-PCR results were highly correlated with
those observed with mRNA-seq (Fig. 5c). These results
demonstrated that SUMOylation of sPRDM16 controls
the expression of genes related to cancer proliferation
and differentiation, suggesting that SUMOylation of
sPRDM16 plays an important role in leukemia cell pro-
liferation and differentiation.
Discussion
In this study, we demonstrated that sPRDM16 promoted
the proliferation and enhanced the self-renewal capacity,
of THP-1, while inhibiting differentiation of these AML
cells. We further confirmed that K568 is a bona fide
sPRDM16 SUMOylation site. Accordingly, mutation of
sPRDM16 SUMOylation site K568 partially abolished the
influence of sPRDM16 on proliferation and differentiation
of AML in vitro and in vivo. Furthermore, THP-1 cells
overexpressing sPRDM16-K568R mutant displayed distinct
a gene expression profile from wild type sPRDM16 follow-
ing incubation with PMA. Our findings suggest that K568
SUMOylation plays an important role in the pathogenesis
of AML.
PRDM16 has previously been reported to be involved
in myeloid and lymphoid malignancies, and to play a
role in the regulation of hematopoietic [12], neuronal
stem cell growth [13], and differentiation of adipose
tissue [14, 17, 26]. It is widely believed that sPRDM16 is
an oncogene [27, 28]. Further, it is well documented that
sPRDM16 promotes AML progression by regulating
gene transcription through direct DNA binding and/or
interaction with transcriptional co-factors and chromatin
modifiers [29]. Accumulating clinical evidence indicates
that deregulation of sPRDM16 is closely associated with
abnormal AML phenotypes [9, 10, 28, 30], implicating
sPRDM16 in AML pathogenesis. Consistent with these
findings, we found that sPRDM16 promoted prolifera-
tion and enhanced self-renewal capacity, while inhibiting
differentiation of THP-1 AML cells.
In addition, increasing evidence suggest that SUMOy-
lation may have a major role in the evolution of the
hematopoietic system and AML. Some studies have indi-
cated that SUMO is an integral component of chromatin
and regulates specific transcriptional programs [31].
Recently, Guillaume Bossis et al. reported that an
important role of SUMOylation is to regulate the ex-
pression of specific genes involved in AML cell response
to chemotherapeutic drugs. and inhibition of the SUMO
pathway reduces AML cell growth in xenograft mice [6].
The transcriptional activity of sPRDM3, a member of
the PR domain family, is negatively regulated by
SUMO1 in acute promyelocytic leukemia (APL) [32].
Using various functional assays to compare overexpres-
sion of PRDM16-WT or sPRDM16-K568R in THP-1
cells, we demonstrated that sPRDM16 SUMOylation
contributed to progression of AML. Furthermore, a
SUMOylation mutant of sPRDM16 attenuated its abil-
ity to facilitate tumor growth and suppress the differen-
tiation of THP-1 cells in vitro. Animal systemic
leukemia transplantation models further indicated that
sPRDM16 SUMOylation may be a risk factor for
leukemia in vivo.
(See figure on previous page.)
Fig. 4 SUMOylation of sPRDM16 enhanced the engraftment of systemic THP-1 transplantation leukemia in NOD.CB17-Prkdcscid/J (NOD/SCID) mice.
Sub-lethally irradiated mice were inoculated via the tail vein with 1 × 107 GFP-labeled THP-1 cells stably infected with Lenti-Vector, sPRDM16–WT or
sPRDM16–K568R. Fluorescent grafts were monitored by flow cytometry. All mice were sacrificed and subjected to subsequent test 30 days
post-transplantation of THP-1 cells. a FACS blots of leukemic cells (GFP+) in the femur bone marrow in mice inoculated with Lenti-Vector,
sPRDM16–WT or sPRDM16–K568R THP-1 cells 30 days post-transplantation. The dot plots showed SSC (y axis) versus GFP intensity (x axis).
b Bar graphs summarized the percentage of leukemic cell (GFP+) in the bone marrow per femur over whole population (n = 5-6). c Dot
blots indicated leukemic cells (GFP+) in mice peripheral blood 30 days post-transplantation of Lenti-Vector, sPRDM16–WT or sPRDM16–K568R THP-1 cells.
The dot plots showed SSC (y axis) versus GFP intensity (x axis). d Percentages of leukemic cells (GFP+) in mice peripheral blood over whole population
(n= 5-6). e H&E staining of marrow cavity of femur section from the mice transplanted with THP-1 cells stably infected with Lenti-Vector, sPRDM16–WT
or sPRDM16–K568R. f Mean animal weight
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Fig. 5 (See legend on next page.)
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Despite the established role of sPRDM16 in leukemia
development, the molecular mechanisms underlying
sPRDM16 SUMOylation-mediated progression of AML
remain elusive. In particular, very few downstream target
genes of sPRDM16 have been identified. Our analysis of
stable THP-1 cell lines generated by polyclonal lentiviral
infection with sPRDM16–WT or sPRDM16–K568R re-
vealed a distinct gene expression profile. mRNA-
sequence data indicated no significant difference in gene
expression between sPRDM16-WT and sPRDM16-
K568R-THP-1 cells in the absence of PMA. Interestingly,
following induction of differentiation by PMA, we found
that 237 genes were differently expressed between
sPRDM16–WT and sPRDM16–K568R-THP-1 cells.
Consequently, we confirmed that KLF10, BCL3, HDAC9,
CCL5, IL6R, LIF and NUMB, all of which are closely re-
lated to differentiation in hematopoietic and leukemic
cells [33–37], are downstream targets of sPRDM16, and
are influenced by SUMOylation. KLF10 is a transcription
factor that regulates differentiation of bone marrow-
derived macrophages [33, 38]. BCL3 plays a critical role
in targeting the differentiation of myeloid progenitors
[34]. The chemokine CCL5 induces selective migration
of monocytes and drives their differentiation [36]. Numb
plays critical roles in cell fate determination as an evolu-
tionary conserved protein [37, 39]. These results indicate
that SUMOylation of sPRDM16 is an important mechan-
ism by which sPRDM16 promotes the growth and prolifer-
ation of hematopoietic progenitors and leukemic cells.
Conclusions
In summary, we have provided evidence that sPRDM16
SUMOylation plays an important role during AML
progression by promoting the growth and inhibiting
differentiation of AML cells in vitro and in vivo. We
further identified significant changes in downstream
genes related to SUMOylation of sPRDM16 during
AML differentiation. As sPRDM16 is frequently over-
expressed in a variety of leukemias, sPRDM16 SUMOy-
lation may be an important regulator of sPRDM16 in
leukemia development.
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